Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 14/20 | 0.50 |
| ▸ | LTB4R2 | Q9NPC1 | 4/20 | 0.48 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.48 |
| ▸ | GP6 | Q9HCN6 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3473870 | 1.00 | AGTR1 (0.50) | AGTR1LTB4R2ABCB11GP6MEN1 | |
| SCHEMBL6443487 | 0.92 | AGTR1 (0.43) | AGTR1LTB4R2ABCB11GP6MEN1 | |
| SCHEMBL6465938 | 0.92 | AGTR1 (0.43) | AGTR1LTB4R2ABCB11GP6MEN1 | |
| SCHEMBL2691 | 0.92 | AGTR1 (0.61) | AGTR1LTB4R2ABCB11GP6 | |
| SCHEMBL2950 | 0.92 | AGTR1 (0.61) | AGTR1LTB4R2ABCB11GP6 | |
| SCHEMBL14193717 | 0.92 | AGTR1 (0.61) | AGTR1LTB4R2ABCB11GP6 | |
| SCHEMBL3473679 | 0.90 | AGTR1 (0.58) | AGTR1LTB4R2ABCB11GP6MEN1 | |
| SCHEMBL3473688 | 0.90 | AGTR1 (0.58) | AGTR1LTB4R2ABCB11GP6MEN1 | |
| SCHEMBL2482 | 0.89 | ALDH1A1 (0.47) | AGTR1LTB4R2ABCB11GP6ALDH1A1 | |
| SCHEMBL3362 | 0.88 | AGTR1 (0.47) | AGTR1LTB4R2ABCB11GP6MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100048654-A1 | USE OF VALSARTAN OR ITS METABOLITE TO IN HIBIT PLATELET AGGREGATION | NOVARTIS PHARMACEUTICALS CORPORATION | 2010-02-25 | — | — | US | disclosed |
| US-20100048654-A1 | USE OF VALSARTAN OR ITS METABOLITE TO IN HIBIT PLATELET AGGREGATION | NOVARTIS PHARMACEUTICALS CORPORATION | 2010-02-25 | — | — | US | disclosed |
| US-20100048654-A1 | USE OF VALSARTAN OR ITS METABOLITE TO IN HIBIT PLATELET AGGREGATION | NOVARTIS PHARMACEUTICALS CORPORATION | 2010-02-25 | — | — | US | disclosed |
| EP-1505965-B1 | USE OF THE METABOLITE OF VALSARTAN TO INHIBIT PLATELET AGGREGATION | NOVARTIS AG (CH) | 2006-08-02 | — | — | EP | disclosed |
| US-20050197372-A1 | Use of valsartan or its metabolite to inhibit platelet aggregation | MALININ ALEX (US) | 2005-09-08 | — | — | US | disclosed |
| EP-1505965-A1 | USE OF VALSARTAN OT ITS METABOLITE TO INHIBIT PLATELET AGGREGATION | Novartis AG (CH) | 2005-02-16 | — | — | EP | disclosed |
| WO-2003094915-A1 | USE OF VALSARTAN OT ITS METABOLITE TO INHIBIT PLATELET AGGREGATION | NOVARTIS AG (CH) | 2003-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048654-A1 | USE OF VALSARTAN OR ITS METABOLITE TO IN HIBIT PLATELET AGGREGATION | PDGFRA, PLAT, PTAFR | AGTR1 34/4885LTB4R2 538/4885ABCB11 1729/4885 |
| US-20050197372-A1 | Use of valsartan or its metabolite to inhibit platelet aggregation | PTAFR, PDGFRA, ACE | AGTR1 14/4885LTB4R2 311/4885ABCB11 2341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.